AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 156 filers reported holding AMYLYX PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,289,243 | -15.1% | 1,545,016 | +0.0% | 0.76% | -4.4% |
| Q2 2023 | $33,317,367 | -21.8% | 1,544,616 | +6.3% | 0.79% | -22.0% |
| Q1 2023 | $42,625,621 | -6.2% | 1,452,816 | +18.1% | 1.02% | -7.0% |
| Q4 2022 | $45,435,087 | +299.8% | 1,229,637 | +204.6% | 1.09% | +271.8% |
| Q3 2022 | $11,365,000 | -39.4% | 403,737 | -58.6% | 0.29% | -46.2% |
| Q2 2022 | $18,761,000 | +46.3% | 974,107 | -2.4% | 0.55% | +69.0% |
| Q1 2022 | $12,828,000 | – | 998,307 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
| Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
| Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
| Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
| Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
| Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
| Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
| Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
| Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |